
Opinion|Videos|April 10, 2025
The Future of Pulmonary Fibrosis Management: Precision Medicine, Biomarkers and AI
Author(s)Eric Cannon, PharmD, FAMCP
Eric Cannon, PharmD, FAMCP, discusses how precision medicine advancements and biomarker development can enable targeted idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) therapies by identifying patient subgroups most likely to benefit from specific interventions. Artificial intelligence (AI) integration offers potential for earlier diagnosis, improved prognostication and personalized treatment optimization through data pattern recognition.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How can advancements in precision medicine and biomarker development improve treatment strategies for pulmonary fibrosis?
- How do you envision AI impacting management strategies of patients with IPF and PPF?
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
FAQ: The uncertain future of enhanced ACA premium subsidies and what it means for U.S. healthcare
2
Myqorzo is now available for rare heart condition at a $108,400 annual price
3
When it comes to quality measures, fewer is viewed as better, says Ben Shirley of PQA | Part 2
4
Could GLP-1s help with cognitive symptoms, pychosis of schizophrenia?
5























